Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The β2 integrin activation pathway is a critical intracellular signaling cascade in leukocytes that regulates their ability to adhere firmly to blood vessel walls and migrate into tissues during immune responses. This process involves conformational changes in β2 integrins—from an inactive bent state to an extended high-affinity state—triggered by signals from chemokine receptors and selectins via inside-out signaling mechanisms. Key cytoplasmic mediators include kinases such as Syk and PI3K, small GTPases like Rap1a, adaptor proteins talin‑1 and kindlin‑3 which bind directly to the cytoplasmic tail of β subunits inducing conformational change necessary for ligand binding. Proper functioning of this pathway is essential for effective leukocyte recruitment during inflammation; defects lead to immunodeficiency while overactivation contributes to chronic inflammatory diseases[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin beta-2 activation pathway (β2 integrin activation pathway).